Unit: Market Access Consulting
Indications: Chronic Kidney disease, post-transplant infection, Limbal stem cell deficiency (LSCD), severe obesity/NASH/T2D
Subject: Value assessment of new product innovations
Method: Deliberative consultation
Year: 2014